Connective tissue growth factor: A fibrogenic master switch in fibrotic liver diseases

Liver International

Volumn 28, Issue 8, 2008, Pages 1065-1079

  Gressner, Olav A ^a   Gressner, Axel M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Connective tissue growth factor; CTGF; Diagnosis; Liver fibrosis; Pathogenesis; Therapy; Translational medicine

Indexed keywords

BIOCHEMICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; OSTEOGENIC PROTEIN 1; SCLEROPROTEIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

BINDING SITE; CELL ADHESION; CELL PROLIFERATION; FIBROGENESIS; HUMAN; LIVER FIBROSIS; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION REGULATION; HUMANS; LIVER CIRRHOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 48949084865     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01826.x     Document Type: Review

References (151)

1. Wake K. Sternzellen in the liver: Perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 1971; 132: 429-62.
2. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
4. Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-63.
5. Gressner OA, Rizk MS, Kovalenko E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start - where will it go. J Gastroenterol Hepatol 2008; Epub ahead of print.
6. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 2007; 6: 7.
7. Ikegami T, Zhang Y, Matsuzaki Y. Liver fibrosis: Possible involvement of EMT. Cells Tissues Organs 2007; 185: 213-21.
8. Desmoulière A. Hepatic stellate cells: The only cells involved in liver fibrogenesis? A dogma challenged. Gastroenterology 2007; 132: 2059-62.
9. Kaimori A, Potter J, Kaimori J, et al. TGF-beta 1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in-vitro. J Biol Chem 2007; 282: 22089-101.
10. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.
11. Kojima T, Takano K, Yamamoto T, et al. Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes. Liver Int 2008; 28: 534-45.
12. Kinnman N, Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 2002; 7: D496-503.
13. Kinnman N, Francoz C, Barbu W, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003; 83: 163-73.
14. Robertson H, Kirby JA, Yip WW, et al. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007; 45: 977-81.
15. Bucala R, Spiegel LA, Chesney AH, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
16. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007; 45: 213-22.
17. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 145-50.
18. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-21.
19. Ruhnke M, Nussler AK, Ungefroren H, et al. Human monocyte-derived neohepatocytes: A promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 2005; 79: 1097-103.
20. Ruhnke M, Ungefroren H, Nussler A, et al. Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 2005; 128: 1774-86.
21. Gressner AM. Mediators of hepatic fibrogenesis. Hepato-Gastroenterol 1996; 43: 92-103.
22. Pinzani M, Rombouts K. Liver fibrosis: From the bench to clinical targets. Digest Liver Dis 2004; 36: 231-42.
23. Bissell DM, Roulot D, George J. Transforming growth factor β and the liver. Hepatology 2001; 34: 859-67.
24. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-β in hepatic fibrosis. Front Biosci 2002; 7: D793-807.
25. Yang Y, Pan X, Lei W, et al. Regulation of transforming growth factor-{beta}1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res 2006; 66: 8617-24.
26. Oberhammer F, Bursch W, Parzefall W, et al. Effect of transforming growth factor beta on cell death of cultured rat hepatocytes. Cancer Res 1991; 51: 2478-85.
27. Gressner AM, Polzar B, Lahme B, Mannherz HG. Induction of rat liver parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor-beta. Hepatology 1996; 23: 571-81.
28. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor {beta} Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-92.
29. Huang SS, Huang JS. TGF-beta control of cell proliferation. J Cell Biochem 2005; 96: 447-62.
30. Cerwenka A, Swain SL. TGF-beta1: Immunosuppressant and viability factor for T lymphocytes. Microbes and Inf 1999; 1: 1291-6.
31. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-93.
32. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-41.
33. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
34. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta 1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8.
35. Kinoshita K, Iimuro Y, Otogawa K, et al. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 2007; 56: 706-14.
36. Sugimoto H, Yang C, Lebleu VS, et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007; 21: 256-64.
37. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective-tissue growth-factor - a cysteine-rich mitogen secreted by human vascular endothelial-cells is related to the src-induced immediate early gene-product Cef-10. J Cell Biol 1991; 114: 1285-94.
38. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125-30.
39. Leask A, Abraham DJ. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-10.
40. Rachfal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitam Horm 2005; 70: 69-103.
41. Brigstock DR, Steffen CL, Kim GY, et al. Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids - Identification as heparin-regulated M-r 10,000 forms of connective tissue growth factor. J Biol Chem 1997; 272: 20275-82.
42. Mcknight AJ, Savage DA, Patterson CC, et al. Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy. J Hum Genet 2006; 51: 383-6.
43. Blom IE, Van Dijk AJ, De Weger RA, et al. Identification of human ccn2* (connective tissue growth factor) promoter polymorphisms. J Clin Pathol-Mol Pathol 2001; 54: 192-6.
44. Fonseca C, Lindahl GE, Ponticos M, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20.
45. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: New targets for antifibrotic therapy. Matrix Biol 2002; 21: 473-82.
46. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469-80.
47. Holmes A, Abraham DJ, Sa S, et al. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276: 10594-601.
48. Holmes A, Abraham DJ, Chen YJ, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003; 278: 41728-33.
49. Muehlich S, Cicha I, Garlichs CD, et al. Actin-dependent regulation of connective tissue growth factor. Am J Physiol Cell Physiol 2007; 292: C1732-38.
50. Leivonen SK, Hakkinen L, Liu D, Kahari VM. Smad3 and extracellular signal-regulated kinase 1/2 coordinately mediate transforming growth factor-beta-induced expression of connective tissue growth factor in human fibroblasts. J Invest Dermatol 2005; 124: 1162-9.
51. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation - requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 2003; 278: 13008-15.
52. Chen YJ, Blom IE, Sa S, et al. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002; 62: 1149-59.
53. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Downregulation by cAMP. FASEB J 1999; 13: 1774-86.
54. Park S-K, Kim J, Seomun Y, et al. Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 2001; 284: 966-71.
55. Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins - implications in mechanical stress-associated pathologies. FEBS J 2006; 273: 3639-49.
56. Schild C, Trueb B. Mechanical stress is required for high-level expression of connective tissue growth factor. Exp Cell Res 2002; 274: 83-91.
57. Abraham DJ, Xu SW, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000; 275: 15220-5.
58. Kothapalli D, Hayashi N, Grotendorst GR. Inhibition of TGF-beta-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. FASEB J 1998; 12: 1151-61.
59. Stratton R, Xu SW, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108: 241-50.
60. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27: 715-23.
61. Wahab NA, Brinkman H, Mason RM. Uptake and intracellular transport of the connective tissue growth factor: A potential mode of action. Biochem J 2001; 359: 89-97.
62. Dziadzio M, Usinger W, Leask A, et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. Q J Med -Int J Med 2005; 98: 485-92.
63. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
64. Roestenberg P, Van Nieuwenhoven FA, Joles JA, et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol-Renal Physiol 2006; 290: F1344-54.
65. Riser BL, Cortes P, Denichilo M, et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report. Kidney Int 2003; 64: 451-8.
66. Kubota S, Kawata K, Yanagita T, et al. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J Biochem 2004; 136: 279-82.
67. Cicha I, Garlichs CD, Daniel WG, Goppelt-Struebe M. Activated human platelets release connective tissue growth factor. Thromb Haemostasis 2004; 91: 755-60.
68. Segarini PR, Nesbitt JE, Li DX, et al. The low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 2001; 276: 40659-67.
69. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands. Biol Chem 1998; 379: 951-64.
70. Mercurio S, Latinkic B, Itasaki N, et al. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 2004; 131: 2137-47.
71. Lamarre J, Hayes MA, Wollenberg GK, et al. An alpha2-macroglobulin receptor-dependent mechanism for the plasma clearance of TGF-beta1 in mice. J Clin Invest 1991; 87: 39-44.
72. Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003; 130: 2779-91.
73. Murawaki Y, Ikuta Y, Koda M, et al. Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 1996; 11: 459-65.
74. Kennedy L, Liu S, Shi-Wen X, et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res 2007; 313: 952-64.
75. Moussad EE, Brigstock DR. Connective tissue growth factor: What's in a name? Mol Genet Metab 2000; 71: 276-92.
76. Gao RP, Ball DK, Perbal B, Brigstock DR. Connective tissue growth factor induces c-fos gene activation and cell proliferation through p44/42 MAP kinase in primary rat hepatic stellate cells. J Hepatol 2004; 40: 431-8.
77. Safadi FF, Popoff SN, Aswald R, et al. Connective tissue growth factor (CTGF) acts as a downstream mediator of TGF-beta1 to induce mesenchymal cell condensation. J Cell Physiol 2007; 210: 398-410.
78. Gao R, Brigstock DR. A novel integrin alpha(5)beta(1) binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut 2006; 55: 856-62.
79. Korner T, Kropf J, Kosche B, et al. Improvement of prognostic power of the Child-Pugh classification of liver cirrhosis by hyaluronan. J Hepatol 2003; 39: 947-53.
80. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Nephron Exp Nephrol 2006; 104: E129-34.
81. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002; 16: 219-21.
82. Yoshida K, Munakata H. Connective tissue growth factor binds to fibronectin through the type I repeat modules and enhances the affinity of fibronectin to fibrin. Biochimica Biophysica Acta (BBA) - General Subjects 2007; 1770: 672-80.
83. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003; 81: 355-63.
84. Grotendorst GR, Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005; 19: 729-38.
85. Davidson ENB, Vitters EL, Mooren FM, et al. Connective tissue growth factor/CCN2 overexpression in mouse synovial lining results in transient fibrosis and cartilage damage. Arthritis Rheum 2006; 54: 1653-61.
86. Kantarci A, Black SA, Xydas CE, et al. Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J Pathol 2006; 210: 59-66.
87. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006; 208: 336-43.
88. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
89. Ito Y, Aten J, Bende RJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-61.
90. Di Mola FF, Friess H, Martignoni ME, et al. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg 1999; 230: 63-71.
91. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999; 21: 693-700.
92. Matsui Y, Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: Implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol 2004; 37: 477-81.
93. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26: 1-9.
94. Dammeier J, Brauchle M, Falk W, et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol 1998; 30: 909-22.
95. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.
96. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
97. Neilson EG. Setting a trap for tissue fibrosis. Nat Med 2005; 11: 373-4.
98. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP. Integration of TGF-b/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 2004; 23: 1155-65.
99. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
100. Wahab NA, Weston BS, Mason RM. Modulation of the TGF beta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005; 307: 305-14.
101. Williams EJ, Gaca MDA, Brigstock DR, et al. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000; 32: 754-61.
102. Abou-Shady M, Friess H, Zimmermann A, et al. Connective tissue growth factor in human liver cirrhosis. Liver 2000; 20: 296-304.
103. Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 968-76.
104. Morikawa H, Tamori A, Nishiguchi S, et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13: 240-5.
105. Kobayashi H, Hayashi N, Hayashi K, et al. Connective tissue growth factor and progressive fibrosis in biliary atresia. Pediatr Surg Int 2005; 21: 12-6.
106. Hayashi N, Kakimuma T, Soma Y, et al. Connective tissue growth factor is directly related to liver fibrosis. Hepato-Gastroenterol 2002; 49: 133-5.
107. Hora C, Negro F, Leandro G, et al. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liv Int 2008; 28: 370-6.
108. Sedlaczek N, Jia JD, Bauer M, et al. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 2001; 158: 1239-44.
109. Gressner O, Lahme B, Demirci I, et al. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710.
110. Weng HL, Ciuclan L, Liu Y, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46: 1257-70.
111. Gressner OA, Lahme B, Siluschek M, et al. Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008; Epub ahead of print.
112. Wickert L, Chatain N, Kruschinsky K, Gressner AM. Glucocorticoids activate TGF-beta induced PAI-I and CTGF expression in rat hepatocytes. Comp Hepatol 2007; 6: 5.
113. Ujike K, Shinji T, Hirasaki S, et al. Kinetics of expression of connective tissue growth factor gene during liver regeneration after partial hepatectomy and d-galactosamine-induced liver injury in rats. Biochem Biophys Res Commun 2000; 277: 448-54.
114. Paradis V, Dargere D, Bonvoust F, et al. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82: 767-73.
115. Gao RP, Brigstock DR. Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res 2003; 27: 214-20.
116. Zheng SZ, Chen AP. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am J Physiol 2006; 290: G883-93.
117. Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta 1. Exp Mol Med 2005; 37: 138-45.
118. Lee SH, Seo GS, Park YN, Sohn DH. Nephroblastoma overexpressed gene (NOV) expression in rat hepatic stellate cells. Biochem Pharmacol 2004; 68: 1391-400.
119. Cimica V, Batusic D, Haralanova-Ilieva B, et al. Serial analysis of gene expression (SAGE) in rat liver regeneration. Biochem Biophys Res Commun 2007; 360: 545-52.
120. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis. Hepatology 2000; 31: 828-33.
121. Wang H, Mengsteab S, Tag CG, et al. Transforming growth factor-beta1 polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005; 11: 1929-36.
122. Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-β 1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002; 316: 83-94.
123. Cheng JH, She H, Han YP, et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G39-49.
124. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 95-107.
125. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006; 43: S1-7.
126. Liu X, Hu H, Yin J. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26: 8-22.
127. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006; 69: 597-607.
128. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006; 7: 513-21.
129. Gressner AM, Weiskirchen R. The tightrope of therapeutic suppression of active transforming growth factor-beta: High enough to fall deeply? J Hepatol 2003; 39: 856-9.
130. Li G, Xie Q, Shi Y, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900.
131. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007; 14: 790-803.
132. Uchio K, Graham M, Dean NM, et al. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 2004; 12: 60-6.
133. Fu MG, Zhang JF, Zhu XJ, et al. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 2001; 276: 45888-94.
134. Hewitson TD, Martic M, Darby IA, et al. Intracellular cyclic nucleotide analogues inhibit in vitro mitogenesis and activation of fibroblasts derived from obstructed rat kidneys. Nephron Exp Nephrol 2004; 96: E59-66.
135. Stratton R, Rajkumar V, Ponticos M, et al. Prostacyclin derivatives prevent the fibrotic response to TGF beta 2 by inhibiting the Ras/MEK/ ERK pathway. FASEB J 2002; 16: 1949-51.
136. Ricupero DA, Rishikof DC, Kuang PP, et al. Regulation of connective tissue growth factor expression by prostaglandin E(2). Am J Physiol 1999; 277: L1165-71.
137. Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005; 16: 2702-13.
138. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-50.
139. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007; 381: 107-13.
140. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007; 11: 1031-51.
141. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 99: 1160-74.
142. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: Biochemistry or biopsy? Ann Clin Biochem 2005; 42: 441-7.
143. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
144. Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 429-38.
145. Roestenberg P, Van Nieuwenhoven FA, Wieten L, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diab Care 2004; 27: 1164-70.
146. Strnad P, Lienau TC, Tao GZ, et al. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 2006; 43: 1354-63.
147. Tamatani T, Kobayashi H, Tezuka K, et al. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998; 251: 748-52.
148. Gressner AM, Yagmur E, Lahme B, et al. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006; 52: 1815-7.
149. Chen YJ, Segarini P, Raoufi F, et al. Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res 2001; 271: 109-17.
150. Chen YL, Abraham DJ, Xu SW, et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 2004; 15: 5635-46.
151. Cheng O, Thuillier R, Sampson E, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transpl 2006; 6: 2292-306.